Evofem Biosciences, Inc.

What they do

Evofem markets PHEXX, an FDA-approved non-hormonal prescription contraceptive vaginal gel used 0-60 minutes before intercourse, launched in the U.S. in September 2020. It acquired global rights to SOLOSEC, a single-dose oral antimicrobial for bacterial vaginosis and trichomoniasis, in July 2024 and relaunched the brand in November 2024. Outside the U.S., it licenses commercial rights through partnerships, including MENA rights to Pharma 1 for both products and a Sub-Saharan Africa distribution agreement for SOLOSEC.

Revenue drivers

• PHEXX (U.S.) — The company's first commercial product, a hormone-free on-demand contraceptive gel; Q1 2026 sales were affected by lower ex-factory sales after wholesalers purchased heavily in December 2025 ahead of a January 2026 price increase.
• SOLOSEC (U.S.) — Single-dose oral antimicrobial for bacterial vaginosis and trichomoniasis; relaunched November 2024, with Q1 2026 net sales helped by higher WAC, a more favorable gross-to-net ratio and higher ex-factory sales.
• Ex-U.S. licensing and distribution — Partnerships with Pharma 1 for MENA and Clovis Davis Pharmaceuticals for Sub-Saharan Africa; management describes these as potential sources of non-dilutive capital in 2026.

Recent performance

Q1 2026 net sales were $0.9 million versus $0.8 million in the prior-year period. Total operating expenses were $5.5 million, and net loss was $5.5 million, or $(0.04) per basic and diluted share, versus net income attributable to common stockholders of $1.0 million in Q1 2025. Q2 2026 revenue was $2.6 million, up from $0.9 million in Q1 2026 but below the $9.6 million reported in Q4 2025. At June 30, 2026, total assets were $7.5 million, total liabilities were $90.0 million, shareholder equity was negative $87.5 million and cash and equivalents were $285,000.

Strategy

Management's stated strategy is to grow PHEXX in the U.S. while diversifying revenue through ex-U.S. commercialization. The company has licensed PHEXX and SOLOSEC rights in MENA to Pharma 1 and signed a Sub-Saharan Africa distribution agreement with Clovis Davis Pharmaceuticals for SOLOSEC. It is advancing regulatory submissions in the UAE and expects non-dilutive capital from these markets in 2026. An investigator-led, NIH-funded Phase 4 trial is comparing single-dose SOLOSEC to multi-dose metronidazole for trichomoniasis.

Risks

• Going concern — The audited financial statements include a statement that there is substantial doubt about the company's ability to continue as a going concern.
• Past-due vendor obligations — The company states it is over 90 days past due on a significant amount of vendor obligations.
• Substantial indebtedness — It may not be able to refinance, extend or repay substantial secured and unsecured debt, including senior secured notes, promissory notes and convertible notes.
• Need for additional capital — It must raise significant additional funds to finance operations and remain a going concern, or risk delaying, reducing or eliminating business initiatives.

Outlook

Management expects non-dilutive capital from the MENA and Sub-Saharan Africa markets in 2026. It is awaiting the Emirates Drug Establishment review of marketing approval submissions for PHEXX and SOLOSEC in the UAE. The company also points to continued recruitment in the NIH-funded Phase 4 SOLOSEC trial.